You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Improved long-term biocompatibility of coronary stents by plasma coating process

    SBC: NANOVA INC.            Topic: NHLBI

    Improved long term biocompatibility of coronary stents by plasma coating process Abstract Drug eluting stentsDEShave been widely used to treat patients of coronary heart diseaseCHDdue to their better ability to control restenosis than bare metal stentsBMSHoweverthere is a high risk of late in stent thrombosis associated with DES after implantation in patientswhich could lead to fatal heart attack ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. IMMEDIATE FIT USING INNOVATIVE TECHNOLOGY PROSTHETIC SYSTEMS

    SBC: IFIT PROSTHETICS, LLC            Topic: N

    ABSTRACT The principal business interestiFIT Prosthetics LLCwith STTR fundingcreated a new transtibial prosthetic device and demonstrated its safetycomfortand functionIn contrast to conventionally made prosthetic limbsthe iFIT prosthesis is easily fit and aligned on the residual limb in a single sessionDue to its substantial adjustability and customized inner linerthe iFIT device is a comfortable ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. OpenBeds: Improving the Delivery of Care for Patients with Drug Addiction

    SBC: Openbeds Inc.            Topic: NIDA

    There is an urgent need for more effective mechanisms that leverage current technologies and best practices to both identify capacity and refer patients to drug treatment facilitiesThe applicant organizationOpenBeds Incis partnering with the non profit MESH Coalitionthree of the largest health care systems offering drug treatment in Indiana and the Indiana Division of Mental Health and AddictionDM ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Cancer Cachexia Therapeutic

    SBC: TENSIVE CONTROLS, INC.            Topic: 102

    Cachexia anorexia syndrome is a life threatening aspect to many diseasesin particular many forms of cancer or therapies for cancerThe obvious symptoms of this disease include lack of appetiteand a loss of lean body mass disproportionate to the reduction in caloric intakeHoweverthe less obvious effects of cachexia include multi organ failuredue to high metabolic rate induced apoptosisprogrammed cel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Unpinning Termination Therapy for Ventricular Tachyarrhythmias

    SBC: CARDIALEN, INC.            Topic: NHLBI

    Project Summary Abstract Sudden cardiac death is a major cause of death around the worldwith nearlysudden deaths per year in the United StatesVentricular fibrillationVFis the most frequent direct causeThe most common strategy for terminating VF is with a singlelargebiphasic high energyHEelectric shock by an implantable cardiac defibrillatorICDDespite their effectivenessthere have been increasing c ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Neonatal hypoxia ischemiaHIremains a major cause of acute perinatal brain injuryleading ultimately to neurologic dysfunction manifesting as cerebral palsymental retardationand epilepsyUnfortunatelycurrent treatment and prevention strategies in newborns are limitedThere are no currently available therapies to prevent treat and or attenuate brain damage in premature infants other than supportive car ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Restimulating memory T cell responses in elderly by a novel, live influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    Respiratory infections with influenza viruses cause severe morbidity and mortality in humans and animals worldwideImportantlyin humansthe majority of morbidity and mortality following flu infection is seen in older individualsrtyears oldYetclear understanding of how aging impacts on innate immune responsesand how to improve vaccine design in this age group is lackingRestimulating preexisting memor ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Anti-Virulence FimH Inhibitors for the Treatment and Prevention of UTIs

    SBC: FIMBRION THERAPEUTICS INC            Topic: NIAID

    Overmillion women suffer from urinary tract infectionsUTIannually in the U Sandof these patients will suffer from recurrent infectionsincluding approximatelypatientsmostly womenwho will suffer from highly recurrentgreater thanepisodes per yearUTIAntimicrobial treatment of UTIs has resulted in increasing antimicrobial resistance among uropathogenic EcoliUPECto first line empiric therapiessuch as tr ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics' reduced genome E. coli strains

    SBC: SCARAB GENOMICS, LLC            Topic: NIAID

    Scarab Genomicsgoal is to commercialize carrier proteins for conjugate vaccine manufactureThis proposal focuses on two bacterial carrier proteins that have been approved by the FDA and that are in use in pre clinical and clinical studiesExoprotein AEPAfrom Pseudomonas aeruginosa and Protein DPDfrom non typeable Haemophilus influenzaeThese proteins are difficult to make by the conventional Ecoli fe ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Complete genome de novo assembly software for the emerging long read sequencing era

    SBC: DNASTAR, INC.            Topic: 400

    Despite the tremendous success of short read next generation sequencingNGStechnologiestheir inherent inability to establish long range connectivity makes fundamental tasks such as genome closurehaplotype phasing and alternatively spliced transcript characterization all but impossibleNowtwo long read sequencing providersPacific BiosciencesPacBioand Oxford Nanopore TechnologiesONTare producing data ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government